

Libbs

About Us

LIBBS AT A GLANCE

- **G** Top 10 Brazilian pharmaceutical
- **Privately held company, r in 1958**
- **Over 3,500 employees**
- **Dedicated to the development, production, and commercialization of ethical products.**

Strong presence in the local market and diverse product portfolio highly regarded by doctors and patients alike.

As an organization, we have a strong track record of performance, a local technical structure & production site, and a regulatory, marketing & access team, which has allowed the company to grow consistently in terms of sales, people, and product portfolio.

In 2023, we were recognized again and for the sixth consecutive time as a Great Place To Work (GPTW), reinforcing our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Libbs, as they strive to build their company, their family and their community.

PARTNERSHIP & COLLABORATIONS

Libbs is seeking new opportunities to drive future growth through licensing opportunities in NCE, value-added medicines, improved branded generic, and biological products in the early or late stages of development.

We are constantly searching for innovative and superior quality products, and are strongly represented in specialties such as cardiovascular, metabolic diseases, gynecology (women's health), central nervous system (CNS), dermatology, oncology, and respiratory.

one of the largest singleused Biotech manufacturing facilities and operations, with 2,000 L bioreactors and a new 500 L biotech plant for bioprocess optimization/scale-up

Modern complex of laboratories dedicated to R&D strong External R&D team focused on collaborating and funding the development of early-stage compounds for unmet medical needs

Libbs offers its partners the advantages of commitment to the long run and a solid organization with manufacturing and marketing capabilities, regulatory expertise, in-depth drug and technology development knowledge, flexible deal structure, fast decision-making, and reliability.

We are open to discussing different kinds of collaborations focusing on innovative portfolios and differentiation with our commitment to provide the next step in the patient's journey.


For more information, visit <u>www.libbs.com.br</u> or contact <u>businessdevelopment@libbs.com.br</u> <u>Libbs Video Presentation</u>



G5 years

100% Brazilian

A Private entity






We transform knowledge into health for







Source: SAP Receita Líquida Libbs

Our Plant
Industrial Park

Galênica 2 Drugs & Biotec



Production of

Biotechnological monoclonal antibodies Semi-synthetics fermentation processes Synthetics chemical synthesis We produced **18** products from the API in 20 dosage forms



Biosimilars

Clinical research

Brazil Research Centers

Ongoing studies - real world (2), dermocosmetics (8)

19 Comple dermoder with m

Completed studies dermocosmetics (18) e phase IV with medication (1)

15

99

10

Investigator Initiative Projects ongoing by PIP and 6 completed





Recognition



(At least 70% required to obtain this certification)



Abr/2022 - Abr/2023

То

We are in the rank of the Great Place to Work -GPTW[®] for fifth year and in the rank 150 Best Companies to Work in Brazil.

We also have an excellent reputation among the audiences with whom we interact - such as doctors, oncology nurses and pharmacists, suppliers and customers. In the Reputation Survey carried out by the company Retrak, we obtained a score of 85.8 among physicians. The other strategic audiences gave us a score of 85.2.

